MicroRNA therapies developer miRagen Therapeutics is scaling back work on its most advanced cancer drug candidate and shifting resources to a compound being developed to treat fibrosis in the lungs.
The pipeline shuffle will be accompanied by a corporate shakeup. Boulder, CO-based miRagen (NASDAQ: MGEN) is also laying off some of its staff. The company said late Wednesday that those changes will leave the company with enough cash to keep going until the fourth quarter of next year.
MiRagen is developing drugs based on microRNA, which are RNA molecules that regulate gene expression and can influence pathways associated with some… Read more »
UNDERWRITERS AND PARTNERS